Assess biopharmaceutical developability across 8 risk dimensions: aggregation propensity, deamidation hotspots, oxidation sites, glycosylation risk, charge heterogeneity, hydrophobic patches, sequence liabilities, and post-translational modification risk. Returns composite score (0-100) with per-dimension breakdown and flagged positions.

Parameters:
  sequence: Protein/antibody amino acid sequence.
  metal_binding_context: Set True for chelators/metal-binding constructs so functional
    Cys/His/carboxylate residues aren't penalized as liabilities (default False).

Returns: {composite_score, risk_dimensions: {aggregation, deamidation, ...}, flagged_positions}